Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Arq to Attend Upcoming Investor Conferences
-
Veriff Report Highlights Deepfake Threats and Protective Strategies
-
Meineke Selects Katapult’s Innovative Lease-to-Own Solution
-
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
-
Acorn’s Q2’24 EPS Improves to $0.11 vs. $0.04 on Revenue Increase in Remote Monitoring and Control Solutions for Backup Power Generators
-
illumin Reports Second Quarter 2024 Financial Results
-
KH Group’s Half-Year Report 2024 publication and webcast
-
Finland-based Quantlytica raises €1 million to launch AI-powered liquidity distribution protocol
-
North Media Q2 2024 Interim Report: Invitation to investor webcast
-
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
-
Bombardier Partners with Alinghi Red Bull Racing, Uniting Sky and Sea
-
Form 8.3 - Keywords Studios plc - Octopus Investments
-
Knight Therapeutics Reports Second Quarter 2024
-
Base Carbon Announces Receipt of US$11.2 Million From Sale of Carbon Credits
-
Parker Reports Fiscal 2024 Fourth Quarter and Full Year Results and Issues Guidance for Fiscal 2025
-
NuVista Energy LTD. Announces Positive Second Quarter 2024 Financial and Operating Results
-
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
-
Kelly Reports Second-Quarter 2024 Earnings
-
Orezone Closes C$64.9 Million Non-Brokered Private Placement
-
Koryx Copper Intersects 72 METERS at 0.38% CuEq; 80 Meters at 0.34% CuEq, Extending Limits of Mineralization at Haib Copper Project, Southern Namibia
-
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
-
Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)
-
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
-
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Cronos Group Reports 2024 Second Quarter Results
-
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
-
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
-
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
-
Nexxen to Announce Second Quarter 2024 Financial Results on August 22, 2024
-
Jeffs’ Brands Supports Fort’s Growth By Leasing a New Warehouse of Over 10,000 square feet in the UK
-
SFL - Invitation to Presentation of Q2 2024 Results
-
Vital Farms Reports Second Quarter 2024 Financial Results and Raises Fiscal Year 2024 Guidance
-
Alliance Trust PLC - Net Asset Value
-
Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
-
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Axogen, Inc. Announces New Leadership Appointments
-
Howard Hughes Holdings Forms Special Committee to Evaluate Potential Take-Private
-
Emerita Intersects 11.4m of Massive Sulfide Grading 4.3% Copper, 48.31 g/t Silver and 1.85 g/t Gold at El Cura, Extending the Deposit at Depth
-
Synlogic Reports Second Quarter 2024 Financial Results
-
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
-
Supremex Announces Results for the Second Quarter of 2024 and Maintains Dividend
-
Hydrofarm Holdings Group Announces Second Quarter 2024 Results
-
Americold Announces Second Quarter 2024 Results
-
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
-
Cerence Announces Third Quarter Fiscal Year 2024 Results
-
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors
